Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilent Technologies Inc (A) vs Synopsys, Inc. (SNPS) Price & Performance

Agilent Technologies IncTrade
Synopsys, Inc.Trade

Price performance (Past 24H)

Key statistics

Agilent Technologies Inc vs Synopsys, Inc. — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Synopsys, Inc. trades at $411.1 (market cap $78.83B). The key difference: Synopsys, Inc. is the larger of the two by market cap, and Agilent Technologies Inc pays a 0.69% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.

ASNPS
Market Cap
$42.00B$78.83B
Sector
HealthTechnology
52-Week High
$157.20$625.80
52-Week Low
$110.24$372.33
Enterprise Value
$43.55B$87.19B
Dividend Yield
0.69%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilent Technologies Inc

Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.

The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.

Synopsys, Inc.

Synopsys (SNPS) trades at $415.99, up 2.47% with strong technical momentum near resistance at $419. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.35 vs. $3.15 expected) and revenue growth to $7.05B in 2025. Recent developments include strategic AI partnerships with AMD and Microsoft, positioning the company at the forefront of chip design innovation.

Outlook remains positive with analyst consensus target of $559.50 suggesting 34% upside, though high P/E of 95.19 and aggressive cash flow investments in 2025-2026 present valuation and execution risks. The stock's bullish technical setup and strong institutional support outweigh near-term concerns for long-term investors.

Returns comparison

Trailing returns across standard periods

About Agilent Technologies Inc

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.

Read more on A

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS